MNG288
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.253
- HEDGEHOG_SIGNALING+0.150
- ESTROGEN_RESPONSE_EARLY+0.097
- TGF_BETA_SIGNALING+0.090
- APICAL_JUNCTION+0.088
- ANDROGEN_RESPONSE+0.082
- APOPTOSIS+0.066
- MYOGENESIS+0.063
- P53_PATHWAY+0.062
- UV_RESPONSE_DN+0.062
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.518
- ANGIOGENESIS-0.390
- MTORC1_SIGNALING-0.311
- TNFA_SIGNALING_VIA_NFKB-0.291
- ADIPOGENESIS-0.289
- GLYCOLYSIS-0.275
- COMPLEMENT-0.268
- PROTEIN_SECRETION-0.268
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.267
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.261
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG320 | — | — | 0.847 |
| 2 | C3N-00293 | — | cohortA1 | 0.785 |
| 3 | MNG957 | — | — | 0.785 |
| 4 | X3b00356a.e947.42f1.8b5f.6dcd789d9272 | — | cohortA1 | 0.769 |
| 5 | MNG491 | — | — | 0.765 |
| 6 | ERR2208935 | — | — | 0.757 |
| 7 | SRR8526730 | — | cohortA1 | 0.745 |
| 8 | BS_9CA93S6D | Diffuse intrinsic pontine glioma | — | 0.742 |
| 9 | SRR29022832 | — | A | 0.742 |
| 10 | MBCProject_0719_T1_RNA | — | A | 0.741 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.253 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.097 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.090 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.088 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.082 | Inavolisib | — uncovered |
| APOPTOSIS | 0.066 | Idelalisib | — uncovered |
| MYOGENESIS | 0.063 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.062 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.062 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.055 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.055 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.045 | Remibrutinib | — uncovered |
| PEROXISOME | 0.035 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.027 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.023 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.007 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.002 | Inavolisib | — uncovered |